Pharmaceutical News

Novo Nordisk's Q1 2025 Financial report Market Trend Financial statements Novo Nordisk Novo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.
FDA Drug Rejections (January-April 2025) FDA From January to April 2025, the FDA rejected six new drug applications, citing issues like clinical data, CMC problems, and third-party manufacturing concerns. Learn more about each case.
Pfizer's Q1 2025 Financial report Market Trend Financial statements Pfizer Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
Eli Lilly's Q1 2025 Financial report Market Trend Financial statements Eli Lilly Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
AstraZeneca's Q1 2025 Financial report Market Trend Financial statements AstraZeneca AstraZeneca's Q1 2025 revenue rose 10% to $13.59B, with strong growth in oncology and China contributing $1.8B. CEO highlights rich pipeline, U.S. expansion, and 2030 $80B revenue goal.
Novartis's Q1 2025 Financial report Market Trend Financial statements Novartis Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
WuXi AppTec's Q1 2025 Financial report Market Trend Financial statements WuXi AppTec WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
Gilead's Q1 2025 Financial report Financial statements Market Trend Gilead Gilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
AbbVie's Q1 2025 Financial report Financial statements AbbVie Market Trend AbbVie’s Q1 2025 report reveals soaring sales of Skyrizi and Rinvoq amid Humira’s decline. Explore how innovation, competition, and strategic shifts are reshaping AbbVie’s future in immunology and beyond.
PD-(L)1 Resistance Hope PD-1 Immunotherapy Oncology ADC Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.